TY - JOUR T1 - Trans-Arterial Chemoembolization of Metastatic Colorectal Carcinoma to the Liver Adopting DC Bead®, Drug-eluting Bead Loaded with Irinotecan: Results of a Phase II Clinical Study JF - Anticancer Research JO - Anticancer Res SP - 4581 LP - 4587 VL - 31 IS - 12 AU - CAMILLO ALIBERTI AU - GIAMMARIA FIORENTINI AU - PIER CARLO MUZZIO AU - FABIO POMERRI AU - MASSIMO TILLI AU - SERGIO DALLARA AU - GIORGIO BENEA Y1 - 2011/12/01 UR - http://ar.iiarjournals.org/content/31/12/4581.abstract N2 - Trans-arterial chemoembolization (TACE) is a promising locoregional therapy for the treatment of primary hepatic tumors and liver metastases. The aim of the study was to define the activity and outcome of using DC Bead, drug-eluting bead, a spherical embolic device capable of being loaded with irinotecan. Patients and Methods: We conducted a double institutional, single arm, phase II clinical study to evaluate TACE adopting this device in 82 patients presenting with metastatic colorectal carcinoma to the liver after failing chemotherapy. The primary endpoints were tumor shrinkage, safety, feasibility, compliance, and overall survival. RECIST criteria were used to assess responses. Quality of life (QoL) was addressed using Edmonton SAS improvement scale. Results: Out of 103 patients considered, 82 were enrolled and underwent a total of 185 treatments of TACE. The median number of TACE was 2.2 (1-4). A post-embolization syndrome was frequently observed. Adverse observed effects were: right upper quadrant pain (40%), fever (80%), nausea (27%) and increased transaminases (70%). The median follow-up was 29 months. Within one month after treatment, each patient received a computed tomograpic scan. It showed reduction of metastatic contrast enhancement in all patients. Responses were 78% at 3 months. After the first treatment, 75 out 82 patients declared an improvement of their well being lasting more than 18 weeks. The median duration of response was 6 (range 3-10) months; the median follow up was 29 (range 7-48) months. The median survival was 25 (range 6-34) months, with progression free survival at 8 (range 4-16) months. Conclusion: We suggest that TACE adopting DC Bead®, drug-eluting bead loaded with irinotecan could be proposed as palliative therapy for unresectable and chemotherapy resistant liver metastases from CRC. ER -